Final Program

360 WEDNESDAY • MAY 18
P10
P11
P12
P13
P14
Facilitator:
P15
P16
P17
P18
P19
Treatment Persistence in a German Real-Life COPD Cohort
(DACCORD)/C.-P. Criee, R. Buhl, P. Kardos, C. Vogelmeier, C.
Mailaender, N. Lossi, H. Worth, Bovenden, Germany, p.A6780
Gender Differences in Baseline Characteristics of Patients with
COPD: A Pooled Analysis of Pivotal Trials of
Indacaterol/Glycopyrronium from the IGNITE Program/S. Fucile, I.
Tsiligianni, K. Mezzi, K. Kostikas, R. Fogel, East Hanover, NJ, p.A6781
Pooled Analyses from PINNACLE-1 and -2: The Novel
LAMA/LABA Co-Suspension Technology
Glycopyrrolate/Formoterol Fixed-Dose Combination Delivered by
MDI Shows Improvement Versus Monocomponents in Patients
with COPD/F.J. Martinez, K.F. Rabe, R. Rodriguez-Roisin, L.M.
Fabbri, G.T. Ferguson, P.W. Jones, S.I. Rennard, S. Siddiqui, C.
Orevillo, P. Darken, C. Reisner, New York, NY, p.A6782
Cardiovascular Safety Profile of a Novel LAMA/LABA
Co-Suspension Technology Fixed-Dose Combination of
Glycopyrrolate/Formoterol Delivered by Metered Dose Inhaler
in Patients with COPD: 24-Hour Holter Monitoring Study/F.J.
Martinez, L.M. Fabbri, S.I. Rennard, S. Sethi, G. Gottschlich, S.
Arora, P. Darken, C. Orevillo, S. Siddiqui, C. Reisner, New York,
NY, p.A6783
The Novel LAMA/LABA Co-Suspension Technology of
Glycopyrrolate/Formoterol Fixed-Dose Combination MDI
Significantly Improves Health Status in Symptomatic Patients
with COPD/F.J. Martinez, L.M. Fabbri, G.T. Ferguson, C. Orevillo,
P. Darken, C. Reisner, New York, NY, p.A6784
S.C. Lazarus, MD, San Francisco, CA
Beneficial Effect of the Novel LAMA/LABA Co-Suspension
Technology of Glycopyrrolate/Formoterol Fixed-Dose
Combination Delivered by MDI in GOLD A and B COPD
Patients: Pooled Analyses from PINNACLE-1 and -2/F.J.
Martinez, K.F. Rabe, R. Rodriguez-Roisin, L.M. Fabbri, G.T.
Ferguson, P.W. Jones, S.I. Rennard, S. Siddiqui, C. Orevillo, P.
Darken, C. Reisner, New York, NY, p.A6785
Impact of Vilanterol, Fluticasone Furoate, or Their
Combination on Exacerbations in COPD Patients with
Moderate Airflow Obstruction: The SUMMIT Trial/F.J. Martinez,
J. Anderson, R. Brook, B. Celli, C. Crim, S. Kilbride, D. Newby, J.
Vestbo, J. Yates, P. Calverley, New York, NY, p.A6786
Effects of Symptom Severity at Baseline on Lung-Function and
SGRQ Responses in the OTEMTOr Studies/F.J. Martinez, R.
Abrahams, G.T. Ferguson, L. Bjermer, L. Gronke, F. Vob, D. Singh,
New York, NY, p.A6787
Long-Term Safety and Tolerability of
Indacaterol/Glycopyrrolate in Moderate-to-Severe COPD
Patients from the US: A Subgroup Analysis from the FLIGHT3
Study/G.T. Ferguson, A.A. Schubert-Tennigkeit, C. Thach, D.
Banerji, Farmington Hills, MI, p.A6788
Benefits of Tiotropium + Olodaterol on Symptoms and
Health-Related Quality of Life in Patients with Moderate to
Severe COPD with Chronic Bronchitis and/or Emphysema/G.T.
Ferguson, R. Abrahams, L. Bjermer, L. Gronke, F. Vob, D. Singh,
Farmington Hills, MI, p.A6789
P20
P21
P22
P23
P24
P25
P26
P27
Facilitator:
P28
Pooled Analyses from PINNACLE-1 and -2: Safety Profile of the
Novel LAMA/LABA Co-Suspension Technology Fixed-Dose
Combination (Glycopyrrolate/Formoterol) Delivered by MDI, in
Patients with Chronic Obstructive Pulmonary Disease
(COPD)/G.T. Ferguson, K.F. Rabe, F.J. Martinez, R.
Rodriguez-Roisin, L.M. Fabbri, P.W. Jones, S.I. Rennard, S.
Siddiqui, C. Orevillo, P. Darken, C. Reisner, Farmington Hills, MI,
p.A6790
Safety and Efficacy of a Novel LAMA/LABA Co-Suspension
Technology Glycopyrrolate/Formoterol Fixed-Dose
Combination Delivered by MDI: Results of a One-Year
Extension Study in Patients with COPD (PINNACLE-3)/N.A.
Hanania, D.P. Tashkin, E. Kerwin, J. Donohue, M. Denenberg, D.
O’Donnell, D. Quinn, S. Siddiqui, C. Orevillo, A. Maes, C. Reisner,
Houston, TX, p.A6791
24-Hour Lung Function Following the Novel LAMA/LABA
Co-Suspension Technology of Glycopyrrolate/Formoterol
Fixed-Dose Combination MDI, in Patients with
Moderate-to-Very-Severe COPD/S. Arora, L. Delacruz, G.
Feldman, K. Pudi, S. Siddiqui, C. Orevillo, A. Maes, C. Reisner,
Columbus, OH, p.A6792
Safety of Inhaled Glycopyrrolate in Patients with
Moderate-to-Severe COPD: Subgroup Analysis from the
Pooled Data of Four Clinical Trials/P. D’Andrea, C. LaForce, A.
Pedinoff, S.D. Miller, A. Yadao, A. Uddin, B. Franke-Bray, East
Hanover, NJ, p.A6793
Cardiovascular Safety of Twice-Daily Inhaled Glycopyrrolate in
Subgroups of Patients with Moderate-to-Severe COPD: Pooled
Analysis from the GEM1, GEM2, FLIGHT1 and FLIGHT2
Studies/E. Kerwin, C. LaForce, A. Pedinoff, A. Yadao, P.
D’Andrea, A. Uddin, B. Franke-Bray, Medford, OR, p.A6794
Improvement in Lung Function with Indacaterol/Glycopyrrolate
(IND/GLY) in Patients with Moderate to Severe COPD from the
US: A Subgroup Analysis from the FLIGHT1 and FLIGHT2
Studies/E. Kerwin, D.A. Mahler, A. FowlerTaylor, S. Maitra, D.
Banerji, Medford, OR, p.A6795
Safety of Indacaterol/Glycopyrrolate Versus Its
Monocomponents and Placebo in US Patients with
Moderate-to-Severe COPD: A Subgroup Analysis from the
FLIGHT1 and FLIGHT2/E. Kerwin, A. FowlerTaylor, C. Thach, M.
Larbig, D. Banerji, Medford, OR, p.A6796
UMEC/VI as Step-Up Therapy from Tiotropium in Moderate
Symptomatic COPD: a Randomized, 12-Week Study/E. Kerwin,
C.J. Kalberg, D. Galkin, C.-Q. Zhu, A. Church, W. Fahy, Medford,
OR, p.A6797
V. Kim, MD, Philadelphia, PA
Efficacy and Safety of Indacaterol/Glycopyrrolate in the US
Versus non-US Population: Comparison of Clinical Data from a
Pooled Analysis of FLIGHT1 and FLIGHT2/D. Banerji, A.
FowlerTaylor, C. Thach, F. Patalano, East Honover, NJ, p.A6798
ATS 2016 • San Francisco